Multiple Sclerosis
Conference Recap
Multiple Sclerosis Highlights From ECTRIMS 2024
Highlights in relapsing-remitting multiple sclerosis from ECTRIMS 2024 include treatment for pediatric-onset MS, safety of frexalimab, pregnancy-...
Hitting a Nerve
Statins for MS (Not)
Everything we do now in medicine is based on both the successes and failures of what came before.
Conference Coverage
sNFl and sGFAP Predict MS Disability in Unique Ways
GFAP might soon join serum neurofilament light chain (sNFl) levels for predicting disability, but each has unique features and they appear to...
Conference Coverage
Time to Revisit the Standard Treatment Approach in Children With MS?
Only a few medications are licensed for pediatric use, indicating it may be time to reconsider the standard treatment approach for this patient...
Conference Coverage
Undertreatment of Women With MS Unjustified
“We believe that pregnancy-related considerations probably still explain the major part of this gap.”
Conference Coverage
McDonald Criteria Update Aims to Simplify, Speed MS Diagnosis
Significant changes to the diagnostic criteria of MS have been proposed. The next steps will include consulting with the wider MS community and...
Conference Coverage
Genetically Driven Depression Tied to Increased MS Disease Activity
This study increases awareness of the link between depression and MS.
Conference Coverage
Ofatumumab MS Study Supports Early Start Over Switch
New extension data from phase 3 ofatumumab RRMS study, show lower long-term disability accumulation with early-start of the more potent therapy...
Conference Coverage
Novel Agent First to Slow Disability in Nonrelapsing Secondary MS
The phase 3 HERCULES trial showed tolebrutinib, an oral Bruton’s tyrosine kinase inhibitor, delayed the time to onset of 6-month confirmed...
Conference Coverage
No Signal of Benefit for Simvastatin in Progressive MS
Conference Coverage
Disability Reduction Is a Twist in Negative BTKi RRMS Trial
In phase 3 RRMS trials, tolebrutinib showed no advantage over teriflunomide for a relapse endpoint, but a disability endpoint advantage might...